EASL Consensus Conference, Feb 1999

• Standard treatment for chronic hepatitis C

  alfa IFN + Ribavirin
  
  • for 6 months in genotype 2/3 and genotype 1 with low viremia (< 800,000 IU/mL)
  • for 12 months in genotype 1 with high viremia

Previous slide

Next slide

Back to first slide

View graphic version